Absolute bioavailability and stereoselective pharmacokinetics of doxepin

References

• ADAMCZYK, M., FISHPAUGH, J. R. and HARRINGTON, C., 1995, Quantitative determination of E- and Z-doxepin and E- and Z-desmethyldoxepin by high-performance liquid chromatography. Therapeutics and Drug Monitoring, 17, 371–376.
   PubMedGoogle Scholar
• AKAIKE, H., 1974, A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716–723.
   Web of Science ®Google Scholar
• BOGAERT, M. G., ROSSEEL, M. T., DEBERDT, R. and VRANCKX, C., 1981, Plasma levels of the cis- and trans-isomers of doxepin and desmethyldoxepin after administration of doxepin to patients. ArzneimittelforschunglDrug Research, 31, 113–115.
   PubMed Web of Science ®Google Scholar
• DILGER, C., SmAnit., Z. and JAEGER, H., 1988, High-performance liquid chromatographic determination of trans-doxepin and desmethyldoxepin. ArzneimittelforschunglDrug Research, 38, 1525–1528.
   Google Scholar
• FAULKNER, R. D., PITTS, W. M., LEE, C. S., LEWIS, W. A. and FN, W. E., 1983, Multiple-dose doxepin kinetics in depressed patients. Clinical and Pharmacological Therapeutics, 34, 509–515.
   PubMed Web of Science ®Google Scholar
• FRIEDEL, R. and RASKIN, M., 1975, Relationship of blood levels of Sinequan to clinical effects in the treatment of depression in aged patients. In J. Mendels (ed.), Sinequan: A Monograph of Recent Studies (New York: Elsevier).
   Google Scholar
• GHABRIAL, H., PRAKASH, C., TACKE, U. G., BLAIR, I. A. and WILKINSON, G. R., 1991, Geometric isomerization of doxepin during its N-demethylation in humans. Drug Metabolism and Disposition, 19, 596–599.
   PubMedGoogle Scholar
• GIBALDI, M., BOYS, R. and FELDMAN, S., 1971, Influence of first pass effect on availability of drugs on oral administration. Journal of Pharmaceutical Science, 60, 1338–1340.
   PubMed Web of Science ®Google Scholar
• GREEN, D., 1978, Clinical importance of doxepin plasma levels. Journal of Clinical Psychiatry, 39, 481–482.
   PubMedGoogle Scholar
• HOBBS, D. C., 1969, Distribution and metabolism of doxepin. Biochemical Pharmacology, 18, 1941–1954.
   PubMed Web of Science ®Google Scholar
• HRDINA, P. D., BAKISH, D., SWENSON, S. and LAPIERRE, Y. D., 1990, Cis- and trans-isomers of doxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Therapeutics and Drug Monitoring, 12, 129–133.
   PubMedGoogle Scholar
• KIMURA, Y., KUME, M. and KAGEYAMA, K., 1972, Doxepin hydrochloride: absorption, distribution, excretion and metabolism of doxepin. Pharmacometrics, 6, 955–971.
   Google Scholar
• Luo, H., HAWES, E. M., McKAY, G., KORCHINSKI, E. D. and MIDHA, K. K., 1991, The quaternary ammonium-linked glucuronide of doxepin: a major metabolite in depressed patients treated with doxepin. Drug Metabolism and Disposition, 19, 722–724.
   PubMed Web of Science ®Google Scholar
• MIDHA, K. K., HUBBARD, J. W., McKAY, G., HAWES, E. M., KORCHINSKI, E. D., GURNSEY, T., COOPER, J. K. and SCHWEDE, R., 1992, Stereoselective pharmacokinetics of doxepin isomers. European Journal of Clinical Pharmacology, 42, 539–544.
   PubMedGoogle Scholar
• PINDER, R. M., BROGDEN, R. N., SPEIGHT, T. M. and AVERY, G. S., 1977, Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs, 13, 161–218.
   PubMed Web of Science ®Google Scholar
• ROSSEEL, M. T., BOGAERT, M. G. and CLAEYS, M., 1978. Quantitative GLC determination of cis- and trans-isomers of doxepin and desmethyldoxepin. Journal of Pharmaceutical Science, 67, 802-805. SCHWARZ, G., 1978, Estimating the dimension of a model. Annals of Statistics, 6, 461–464.
   Google Scholar
• SHU, Y. Z., HUBBARD, J. W., COOPER, J. K., McKAY, G., KORCHINSKI, E. D., KUMAR, R. and MIDHA, K. K., 1990a, The identification of urinary metabolites of doxepin in patients. Drug Metabolism and Disposition, 18, 735–741.
   PubMedGoogle Scholar
• Sim, Y. Z., HUBBARD, J. W., McKay, G. and MIDHA, K. K., 1990b, Identification of phenolic doxepin glucuronides from patient urine and rat bile. Drug Metabolism and Disposition, 18, 1096–1099.
   PubMedGoogle Scholar
• VIRTANEN, R., SCHEININ, M. and IisAw, E., 1980, Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharnzacologica et Toxicologica Copenhagen, 47, 371–376.
   PubMedGoogle Scholar
• WARD, N. G., BLOOM, V. L., WILSON, L., RASKIND, M. and RAISYS, V. A., 1982, Doxepin plasma levels and therapeutic response in depression: preliminary findings. Journal of Clinical Psychopharmacology, 2, 126–128.
   PubMedGoogle Scholar
• WECKER, M. T., WOODWORTH, J. R., AMSEL, L. P., HINSVARK, O. N. and ROTENBERG, K. S., 1986, Pharmacokinetic evaluation of two doxepin products. Clinical Therapeutics, 8, 342–347.
   PubMedGoogle Scholar
• WHALL, T. J. and DOKLADALOVA, J., 1979, High-performance liquid chromatographic determination of (Z)- and (E)-doxepin hydrochloride isomers. Journal of Pharmaceutical Science, 68, 1454–1456.
   PubMedGoogle Scholar
• YAMAOKA, K. T., 1978, Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmacology, 6, 165–175.
   PubMedGoogle Scholar
• YAK, J. H., HUBBARD, J. W., McKay, G. and MIDHA, K. K., 1997, Stereoselective and simultaneous measurement of cis- and trans-isomers of doxepin and N-desmethyldoxepin in plasma or urine by high-performance liquid chromatography. Journal of Chromatography B, 691, 131–138.
   PubMedGoogle Scholar
• ZIEGLER, V. E., &Gus, J. T., WYLIE, L. T., ROSEN, S. H., HAWF, D. J. and CORYELL, W. H., 1978, Doxepin kinetics. Clinical and Pharmacological Therapeutics, 23, 573–579.
   Google Scholar